GRAIL/$GRAL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Ticker
$GRAL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,000
ISIN
US3847471014
Website
GRAIL Metrics
BasicAdvanced
$1.7B
-
-$58.51
-
-
Price and volume
Market cap
$1.7B
52-week high
$63.99
52-week low
$12.33
Average daily volume
1.5M
Financial strength
Current ratio
9.705
Quick ratio
9.255
Long term debt to equity
2.127
Total debt to equity
2.665
Profitability
EBITDA (TTM)
-496.632
Gross margin (TTM)
-58.18%
Net profit margin (TTM)
-1,464.53%
Operating margin (TTM)
-500.29%
Effective tax rate (TTM)
8.16%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-11.98%
Return on equity (TTM)
-62.22%
Valuation
Price to revenue (TTM)
12.124
Price to book
0.71
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
-3.389
Free cash flow yield (TTM)
-29.51%
Free cash flow per share (TTM)
-1,429.28%
Growth
Revenue change (TTM)
30.47%
Earnings per share change (TTM)
21.85%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Bulls say / Bears say
GRAIL's Galleri test achieved a 45% year-over-year growth in U.S. revenue, with over 137,000 tests sold in 2024, indicating strong market adoption. (prnewswire.com)
The company has secured strategic partnerships, including integration with Quest Diagnostics and TRICARE coverage, enhancing accessibility and potential market reach. (prnewswire.com)
GRAIL ended 2024 with a strong cash position of $767 million, extending its financial runway into 2028, which supports ongoing operations and development. (prnewswire.com)
Despite revenue growth, GRAIL reported a net loss of $2 billion for the full year 2024, an increase of 38% compared to 2023, raising concerns about profitability. (prnewswire.com)
The company faces significant net losses and relies heavily on the Galleri test for revenue, indicating a lack of product diversification. (gurufocus.com)
GRAIL's recent spin-off from Illumina presents potential financial constraints and challenges in establishing independent operations. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
GRAIL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GRAIL stock?
GRAIL (GRAL) has a market cap of $1.7B as of June 20, 2025.
What is the P/E ratio for GRAIL stock?
The price to earnings (P/E) ratio for GRAIL (GRAL) stock is 0 as of June 20, 2025.
Does GRAIL stock pay dividends?
No, GRAIL (GRAL) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next GRAIL dividend payment date?
GRAIL (GRAL) stock does not pay dividends to its shareholders.
What is the beta indicator for GRAIL?
GRAIL (GRAL) does not currently have a Beta indicator.